Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay

Background Expansion of HIV viral load (VL) testing services are required to meet increased targets for monitoring patients on antiretroviral treatment. South Africa currently tests >4million VLs per annum in 16 highly centralised, automated high-throughput laboratories. The Xpert HIV-1 VL assay (Cepheid) was evaluated against in-country predicates, the Roche Cobas Taqmanv2 and Abbott HIV-1RT, to investigate options for expanding VL testing using GeneXpert’s random access, polyvalent capabilities and already established footprint in South Africa with the Xpert MTB/RIF assay (207 sites). Additionally, the performance of Xpert HIV-1VL on alternative, off-label specimen types, Dried Blood Spots (DBS) and whole blood, was investigated. Method Precision, accuracy (agreement) and clinical misclassification (1000cp/ml) of Xpert HIV-1VL plasma was compared to Taqmanv2 (n = 155) and Abbott HIV-1 RT (n = 145). Misclassification of Xpert HIV-1VL was further tested on DBS (n = 145) and whole blood (n = 147). Results Xpert HIV-1VL demonstrated 100% concordance with predicate platforms on a standardised frozen, plasma panel (n = 42) and low overall percentage similarity CV of 1.5% and 0.9% compared to Taqmanv2 and Abbott HIV-1 RT, respectively. On paired plasma clinical specimens, Xpert HIV-1VL had low bias (SD 0.32–0.37logcp/ml) and 3% misclassification at the 1000cp/ml threshold compared to Taqmanv2 (fresh) and Abbott HIV-1 RT (frozen), respectively. Xpert HIV-1VL on whole blood and DBS increased misclassification (upward) by up to 14% with increased invalid rate. All specimen testing was easy to perform and compatible with concurrent Xpert MTB/RIF Tuberculosis testing on the same instrument. Conclusion The Xpert HIV-1VL on plasma can be used interchangeably with existing predicate platforms in South Africa. Whole blood and DBS testing requires further investigation, but polyvalency of the GeneXpert offers a solution to extending VL testing services.

[1]  Michaela Cvitkovic.  Point-of-Care Testing , 2011, Critical care nursing quarterly.

[2]  M. Arnedo,et al.  Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya , 2012, PloS one.

[3]  Maria Cristina Marazzi,et al.  Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. , 2016, Journal of virological methods.

[4]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[5]  Melanie Mackay,et al.  Use of a Prequalification Panel for Rapid Scale-Up of High-Throughput HIV Viral Load Testing , 2012, Journal of Clinical Microbiology.

[6]  Wendy Stevens,et al.  Evaluation of the Abbott m2000 RealTime Human Immunodeficiency Virus Type 1 (HIV-1) Assay for HIV Load Monitoring in South Africa Compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 Assays , 2009, Journal of Clinical Microbiology.

[7]  J. W. Lewis,et al.  A note on concordance correlation coefficient. , 2000, PDA journal of pharmaceutical science and technology.

[8]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[9]  Deborah K Glencross,et al.  Multiple method comparison: Statistical model using percentage similarity , 2003, Cytometry. Part B, Clinical cytometry.

[10]  Deborah K. Glencross,et al.  An Integrated Tiered Service Delivery Model (ITSDM) Based on Local CD4 Testing Demands Can Improve Turn-Around Times and Save Costs whilst Ensuring Accessible and Scalable CD4 Services across a National Programme , 2014, PloS one.

[11]  B. Kana,et al.  Dried Culture Spots for Xpert MTB/RIF External Quality Assessment: Results of a Phase 1 Pilot Study in South Africa , 2011, Journal of Clinical Microbiology.

[12]  Orna Mor,et al.  Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load , 2015, Journal of Clinical Microbiology.

[13]  L. Bilić-Zulle,et al.  Comparison of methods: Passing and Bablok regression. , 2011, Biochemia medica.

[14]  N. Cox,et al.  A Note on the Concordance Correlation Coefficient , 2002 .

[15]  G. Mahon.  A Proposal for Strength-of-Agreement Criteria for Lin’s Concordance Correlation Coefficient , 2005 .

[16]  B. Kana,et al.  Performance Monitoring of Mycobacterium tuberculosis Dried Culture Spots for Use with the GeneXpert System within a National Program in South Africa , 2013, Journal of Clinical Microbiology.